申请人:BAsilea Parmaceutica AG
公开号:US06740642B2
公开(公告)日:2004-05-25
The invention provides new macrolides antibiotics of formula I with improved biological properties and improved stability of the formula
wherein
R1 is hydrogen, cyano, —S(L)mR2, —S(O)(L)mR2, or —S(O)2(L)mR2;
L represents —(CH2)n— or —(CH2)nZ(CH2)n′—;
m is 0 or 1;
n is 1, 2, 3, or 4;
n′ is 0, 1, 2, 3, or 4;
Z is O, S or NH;
R2 is hydrogen, alkyl, heterocyclyl or aryl; which heterocyclyl and the aryl groups may be further substituted;
* indicates a chiral center which is in the (R) or (S) form,
as well as a pharmaceutically acceptable acid addition salts or in vivo cleavable esters thereof.
本发明提供了具有改善生物学性质和改善配方稳定性的新的式I大环内酯类抗生素,其中R1是氢、氰、—S(L)mR2、—S(O)(L)mR2或—S(O)2(L)mR2;L代表—(CH2)n—或—(CH2)nZ(CH2)n′—;m为0或1;n为1、2、3或4;n′为0、1、2、3或4;Z为O、S或NH;R2为氢、烷基、杂环基或芳基;其中杂环基和芳基基团可以进一步取代;*表示手性中心,其为(R)或(S)形式,以及其药物可接受的酸盐或体内可裂解酯。